GlassScriptPhysician profile
Todd M Antin
NPI 1598714073
$1,019,140.35
in general payments reported to CMS, 2019-2025
44 companies · $165K in 2025
The $165K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194K · 2020: $101K · 2021: $152K · 2022: $128K · 2023: $114K · 2024: $165K · 2025: $165K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $346K · Consulting Fee: $54K · Travel and Lodging: $30K · Food and Beverage: $14K · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $345,935.45 |
| Consulting Fee | $53,874.50 |
| Travel and Lodging | $30,326.10 |
| Food and Beverage | $14,016.18 |
| Education | $122.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $449,475.18 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $100,034.87 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $90,714.56 | 2019-2025 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $81,416.79 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $77,491.02 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $45,001.74 | 2019-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $29,617.49 | 2021-2023 | Vraylar |
| Eisai INC. | $27,240.92 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $24,231.17 | 2024-2025 | Cobenfy |
| Allergan, INC. | $22,371.33 | 2019-2021 | |
| Axsome Therapeutics, INC. | $21,505.68 | 2022-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $16,994.35 | 2019-2025 | Invega Sustenna, Spravato |
| Alkermes, INC. | $9,819.52 | 2019-2024 | Aristada, Lybalvi, Vivitrol |
| Biogen, INC. | $6,647.90 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $5,955.35 | 2023 | Quviviq |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $5,020.05 | 2019-2025 | Trintellix |
| Lundbeck LLC | $1,096.22 | 2019-2025 | Abilify Maintena, Rexulti, Brintellix |
| Supernus Pharmaceuticals, INC. | $888.42 | 2021-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $800.46 | 2019-2022 | |
| Livanova USA, INC. | $459.12 | 2021-2023 | Vns Therapy Symmetry Model 8103 Generator |
| Indivior INC. | $304.57 | 2020-2023 | Perseris |
| Acadia Pharmaceuticals INC | $278.83 | 2021-2025 | Nuplazid |
| Jazz Pharmaceuticals INC. | $250.26 | 2019-2022 | |
| Novo Nordisk INC | $214.26 | 2020-2023 | Wegovy, Saxenda |
| Merck Sharp & Dohme LLC | $145.51 | 2019-2023 | Belsomra |
| Corium, LLC | $137.53 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $132.91 | 2020-2024 | Jornay Pm |
| Tris Pharma INC | $128.57 | 2022-2025 | Dyanavel Xr |
| Noven Therapeutics, LLC | $97.96 | 2020-2023 | Secuado, Xelstrym |
| Alfasigma USA, INC. | $89.08 | 2022 | |
| Bausch Health US, LLC | $71.77 | 2019-2025 | Aplenzin, Wellbutrin |
| Shire North American Group INC | $69.03 | 2019 | |
| Collegium Pharmaceutical, INC. | $61.31 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $55.41 | 2020-2021 | |
| Neos Therapeutics, LP | $51.99 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $47.28 | 2021-2022 | |
| Vertical Pharmaceuticals, LLC | $40.99 | 2020 | |
| Almatica Pharma LLC | $40.74 | 2021-2024 | Loreev Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $33.31 | 2022 | |
| Currax Pharmaceuticals LLC | $27.08 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $22.38 | 2020 | |
| Harmony Biosciences LLC | $20.81 | 2024 | |
| Owp Pharmaceuticals, INC. | $20.73 | 2019 | |
| Tempus Ai, INC | $15.90 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Antin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.